176 related articles for article (PubMed ID: 27534746)
1. Major methylation alterations on the CpG markers of inflammatory immune associated genes after IVIG treatment in Kawasaki disease.
Li SC; Chan WC; Huang YH; Guo MM; Yu HR; Huang FC; Kuo HC; Kuo HC
BMC Med Genomics; 2016 Aug; 9 Suppl 1(Suppl 1):37. PubMed ID: 27534746
[TBL] [Abstract][Full Text] [Related]
2. Identifying genetic hypomethylation and upregulation of Toll-like receptors in Kawasaki disease.
Huang YH; Li SC; Huang LH; Chen PC; Lin YY; Lin CC; Kuo HC
Oncotarget; 2017 Feb; 8(7):11249-11258. PubMed ID: 28061462
[TBL] [Abstract][Full Text] [Related]
3. FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki Disease.
Kuo HC; Hsu YW; Wu MS; Woon PY; Wong HS; Tsai LJ; Lin RK; Klahan S; Hsieh KS; Chang WC
Mediators Inflamm; 2015; 2015():564625. PubMed ID: 26089602
[TBL] [Abstract][Full Text] [Related]
4. Multiomics analyses identified epigenetic modulation of the S100A gene family in Kawasaki disease and their significant involvement in neutrophil transendothelial migration.
Huang LH; Kuo HC; Pan CT; Lin YS; Huang YH; Li SC
Clin Epigenetics; 2018 Nov; 10(1):135. PubMed ID: 30382880
[TBL] [Abstract][Full Text] [Related]
5. Identification of an association between genomic hypomethylation of FCGR2A and susceptibility to Kawasaki disease and intravenous immunoglobulin resistance by DNA methylation array.
Kuo HC; Chang JC; Kuo HC; Yu HR; Wang CL; Lee CP; Huang LT; Yang KD
Arthritis Rheumatol; 2015 Mar; 67(3):828-36. PubMed ID: 25470559
[TBL] [Abstract][Full Text] [Related]
6. HAMP promoter hypomethylation and increased hepcidin levels as biomarkers for Kawasaki disease.
Huang YH; Kuo HC; Li SC; Cai XY; Liu SF; Kuo HC
J Mol Cell Cardiol; 2018 Apr; 117():82-87. PubMed ID: 29501389
[TBL] [Abstract][Full Text] [Related]
7. Identification of increased expression of activating Fc receptors and novel findings regarding distinct IgE and IgM receptors in Kawasaki disease.
Chang LS; Ming-Huey Guo M; Lo MH; Kuo HC
Pediatr Res; 2021 Jan; 89(1):191-197. PubMed ID: 31816620
[TBL] [Abstract][Full Text] [Related]
8. Relationship between T-cell HLA-DR expression and intravenous immunoglobulin treatment response in Kawasaki disease.
Wakiguchi H; Hasegawa S; Suzuki Y; Kudo K; Ichiyama T
Pediatr Res; 2015 Apr; 77(4):536-40. PubMed ID: 25580740
[TBL] [Abstract][Full Text] [Related]
9. FCN1 (M-ficolin), which directly associates with immunoglobulin G1, is a molecular target of intravenous immunoglobulin therapy for Kawasaki disease.
Okuzaki D; Ota K; Takatsuki SI; Akiyoshi Y; Naoi K; Yabuta N; Saji T; Nojima H
Sci Rep; 2017 Sep; 7(1):11334. PubMed ID: 28900133
[TBL] [Abstract][Full Text] [Related]
10. Exploring the genes associated with the response to intravenous immunoglobulin in patients with Kawasaki disease using DNA microarray analysis.
Xing Y; Wang H; Liu X; Yu X; Chen R; Wang C; Yu X; Sun L
Exp Mol Pathol; 2015 Feb; 98(1):7-12. PubMed ID: 25449331
[TBL] [Abstract][Full Text] [Related]
11. NLRC4 methylation and its response to intravenous immunoglobulin therapy in Kawasaki disease: a case control study.
Yu B; Zheng B; Shen Y; Shen Y; Qiu H; Wu L; Chen Y; Cai X; Wu J; Hong Q
BMC Pediatr; 2024 Mar; 24(1):190. PubMed ID: 38493129
[TBL] [Abstract][Full Text] [Related]
12. Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease.
Guo MM; Tseng WN; Ko CH; Pan HM; Hsieh KS; Kuo HC
Allergy; 2015 Mar; 70(3):310-8. PubMed ID: 25585854
[TBL] [Abstract][Full Text] [Related]
13. Exploring the relationship between pyroptosis, infiltrating immune cells and Kawasaki disease with resistance to intravenous immunoglobulin (IVIG) via bioinformatic analysis.
Xie Y; Han B
Immunobiology; 2022 Sep; 227(5):152261. PubMed ID: 36029669
[TBL] [Abstract][Full Text] [Related]
14. High-dose intravenous immunoglobulin downregulates the activated levels of inflammatory indices except erythrocyte sedimentation rate in acute stage of Kawasaki Disease.
Lee KY; Lee HS; Hong JH; Han JW; Lee JS; Whang KT
J Trop Pediatr; 2005 Apr; 51(2):98-101. PubMed ID: 15677370
[TBL] [Abstract][Full Text] [Related]
15. Molecular and immunological biomarkers to predict IVIg response.
Galeotti C; Kaveri SV; Bayry J
Trends Mol Med; 2015 Mar; 21(3):145-7. PubMed ID: 25680699
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional regulation by infliximab therapy in Kawasaki disease patients with immunoglobulin resistance.
Ogihara Y; Ogata S; Nomoto K; Ebato T; Sato K; Kokubo K; Kobayashi H; Ishii M
Pediatr Res; 2014 Sep; 76(3):287-93. PubMed ID: 24964229
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulin therapy induces neutrophil apoptosis in Kawasaki disease.
Tsujimoto H; Takeshita S; Nakatani K; Kawamura Y; Tokutomi T; Sekine I
Clin Immunol; 2002 May; 103(2):161-8. PubMed ID: 12027421
[TBL] [Abstract][Full Text] [Related]
18. Hepcidin-Induced Iron Deficiency Is Related to Transient Anemia and Hypoferremia in Kawasaki Disease Patients.
Huang YH; Kuo HC; Huang FC; Yu HR; Hsieh KS; Yang YL; Sheen JM; Li SC; Kuo HC
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187366
[TBL] [Abstract][Full Text] [Related]
19. The B cell superantigen-like interaction of intravenous immunoglobin (IVIG) with Fab fragments of V(H) 3-23 and 3-30/3-30.5 germline gene origin cloned from a patient with Kawasaki disease is enhanced after IVIG therapy.
Leucht S; Uttenreuther-Fischer MM; Gaedicke G; Fischer P
Clin Immunol; 2001 Apr; 99(1):18-29. PubMed ID: 11286538
[TBL] [Abstract][Full Text] [Related]
20. Increase expression of CD177 in Kawasaki disease.
Huang YH; Lo MH; Cai XY; Liu SF; Kuo HC
Pediatr Rheumatol Online J; 2019 Apr; 17(1):13. PubMed ID: 30943984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
